Immunoglobulin response to intravenous streptokinase in acute myocardial infarction

Mary Lynch, W A Littler, B L Pentecost, R A Stockley

Abstract

Objective—To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction.

Design—Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay.

Setting—Coronary care unit in a general hospital.

Patients—48 patients with acute myocardial infarction: 22 patients had venous blood samples taken at presentation only; serial blood samples were taken from 20 patients who then received thrombolytic therapy with streptokinase and six patients who were unsuitable for thrombolytic therapy.

Results—Titres of antibodies to streptokinase were low at presentation in 36 (75%) of the 48 patients. Serial measurements made in 20 patients showed the virtual disappearance of antibody within the first 24 hours. This was followed by a steady increase in the specific IgG1 titre, which peaked at day 14 before gradually declining. Values at one year remained significantly higher than baseline values. There was no evidence of an IgM response in the patients studied.

Conclusion—Low titres of antibodies to streptokinase were widespread in the population. Antibody was consumed after treatment and the subsequent immunoglobulin rise suggested a secondary immune response; the recently described neutralising capacity to streptokinase is probably related to this antibody.

Thrombolysis is now a routine treatment for acute myocardial infarction. It improves morbidity by reducing infarct size and reduces overall mortality. Streptokinase is the most widely used and least expensive thrombolytic agent; in the United Kingdom more experience has been gained with this agent than with any other. It is most often produced by \( \beta \) haemolytic streptococci group C but is also produced by groups A, D, and E. Because streptokinase is a foreign protein it is antigenic, unlike some other thrombolytic agents such as tissue plasminogen activator or urokinase. Studies of the dose of streptokinase required to achieve a thrombolytic state showed that antibodies to streptokinase were widespread in the community. The presence of these antibodies raises the possibility of an adverse immune reaction after treatment with streptokinase.

There are few published reports on the allergic aspect of thrombolytic therapy with streptokinase and these are mainly anecdotal. The reported incidence of allergic reactions varies from 1.7% to 18%. These reactions include acute anaphylaxis, serum sickness, and delayed hypersensitivity. Nevertheless, the relation of the reactions to the immune response is poorly understood. Currently, it is recommended that streptokinase treatment should not be repeated between three days and six months after the initial dose.

The purpose of the present study was to devise assays to assess and follow the antibody response in patients given streptokinase for acute myocardial infarction so that the safety of streptokinase therapy can be determined more reliably.

Patients and methods

We studied 48 patients (38 men and 10 women, aged 42–80), with acute myocardial infarction. Myocardial infarction was diagnosed on the basis of chest pain and definite electrocardiographic changes (ST elevation > 2 mm or T wave inversion in both). Twenty-two of the patients had a venous blood sample taken at presentation only. A further 20 patients who were suitable for thrombolytic therapy with streptokinase and six patients in whom streptokinase was contraindicated (duration of chest pain > 24 hours, peptic ulceration, recent surgery etc) were followed for up to one year. For these 26 patients, 10 ml of venous blood was taken at admission or immediately before treatment with streptokinase; within 24 hours after treatment or admission; on days 2–4; days 7, 14, and 28; and then at intervals of approximately 2, 4, 6, 8, 10 months, and one year after treatment (samples were usually taken within seven days of each time point after one month).

Enzyme linked immunosorbent assays were developed for IgG and the IgG1 subclass by the methods of Voller et al. In brief, the wells of microtitre plates (Gibco, UK) were coated with 200 \( \mu l \) of 300 IU/ml of streptokinase (KabiVitrum Pharmaceuticals) in 0.05 mol/l carbonate/bicarbonate buffer (pH 9.5) and incubated for 16 hours at 4°C. The plate was then washed three times in phosphate buffer, rinsed, and incubated with polyclonal antibody to streptokinase (Amersham International) and washed again. The plates were coated with rabbit anti-human IgG (Biogenex, USA) followed by peroxidase conjugated anti-rabbit IgG (Amersham International) and developed with 2, 2'-azino-bis (3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (Amersham International). The absorbance was measured at 405 nm. A standard curve was generated using serial dilutions of an IgG pool from patients treated with streptokinase.

Lung Immunobiochemical Research Laboratory, Department of Cardiology, General Hospital, Birmingham; and Department of Cardiology, Queen Elizabeth Medical Centre, Birmingham M Lynch W A Littler B L Pentecost R A Stockley Correspondence to Dr Mary Lynch, Department of Cardiology, The General Hospital, Steelhouse Lane, Birmingham B4 6NH. Accepted for publication 29 April 1991
buffered saline with 0.01% Tween to remove any unbound antigen. Several dilutions of patient serum in the same buffer were then added to the wells and incubated for two hours at room temperature. The plates were again washed three times with buffer to remove unbound antibody. Horseradish peroxidase conjugated to sheep anti-human immunoglobulin (Immunodiagnostic Research Laboratory, University of Birmingham) was then added and incubated for a further two hours at room temperature. The plates were again washed to remove unbound antiglobulin, hydrogen peroxidase/α-phenylenediamine (Sigma, UK) in phosphate/citrate buffer (pH 5.0) was then added and the incubation was allowed to continue. When the colour change of a known positive standard on the plate reached a pre-determined value the reaction was stopped by the addition of 0.5 mol/l citric acid. The optical density of each well was read at 490 nm with a spectrophotometer (Dynatech Laboratories, UK).

Assays were devised to measure total IgG, IgG1, IgG2, IgG3, IgG4, and IgM. Standard IgG and IgG1 curves were generated from serum obtained from a patient who had been treated with streptokinase 10 days before (fig 1), and the IgM standard curve was generated from a known positive serum sample (kindly provided by Professor M Dykeiwicz, Department of Immunology, Northwestern University Medical School, Illinois, USA).

Results were expressed with reference to a fixed dilution on a standard curve that was included on every plate. This fixed titre was taken as a 1 in 6000 dilution of the standard serum for IgG and as a 1 in 4000 dilution for IgG1. The optical density value corresponding to the standard fixed dilution was obtained and the corresponding dilution giving the same optical density was derived from the dilution curve for each patient sample. The value obtained in this way from the patient dilution curve was taken as the result for that patient’s serum. The reciprocal of the dilution was taken as the antibody titre (fig 2). Where undiluted patient serum did not achieve the optical density of the fixed standard plasma dilution the result was taken as zero for statistical purposes.

The validity of the assay was confirmed by pre-incubating pure streptokinase with positive serum in a separate experiment. When the sample was tested subsequently with the ELISAs a negative result was obtained.

The reproducibility of the assays was determined at the upper and lower ranges. For the low antibody titres we tested a patient’s sample obtained before treatment. We tested within batch reproducibility by measuring the same sample six times on the same plate. At a mean IgG titre of 19 the within batch coefficient of variation (CV) was 14.7%. It was 12.7% for IgG1 (mean titre = 12). Between batch reproducibility was assessed by assaying the same sample six times on different days. The between batch CV was 29% for IgG and 31.8% for IgG1.

For the high titres the reproducibility was assessed by using a patient’s sample obtained 14 days after streptokinase treatment. At a mean IgG titre of 4200 the within batch CV was 6.9% and the between batch CV was 12.9%. Results for IgG1 (mean titre = 1750) gave a within batch CV of 7.7% and between batch CV of 14.2%.

Total plasma IgG and IgM were assessed by single radial immunodiffusion11 12 on prepoured plates (Binding Site, University of Birmingham) at presentation in the 20 patients followed after streptokinase therapy and the six patients who were not treated with streptokinase.

All results are expressed as mean (SE). The statistical significance of differences between patient groups and between daily data was determined by the Wilcoxon rank sum test for paired and unpaired data.

All patients gave informed consent and the study was approved by the local ethics committee.

Results

Twelve of the 48 patients had no detectable IgG anti-streptokinase antibody before treatment. The remaining 36 patients had titres varying from 1 to 140. Figure 3 summarises the distribution of these titres.

Figure 4 shows the time course of the IgG response to intravenous streptokinase infusion in 20 patients. At presentation 16 of the patients had a detectable antibody titre (mean baseline titre for all 20 patients was 14-63 (4)). After infusion of streptokinase the titre showed a significant fall (p = 0.003) and became
Immunoglobulin baseline IgG patients. The 48 indicate the histograms respectively. the titres (axis) of

Figure 3 Distribution of baseline IgG titres of the 48 patients. The horizontal axis indicates the reciprocal of the antibody titre. The histograms indicate the number of patients (vertical axis) with that titre. Two patients were off the scale and had baseline titres of 80 and 140 respectively.

undetectable in 17 of the patients (mean titre 3 (2)). Subsequently there was a gradual increase and by day 4 the titre (91 (41)) was significantly higher than baseline concentrations (p = 0.018). The titre increased further by day 7 reaching a peak on day 14 (mean titre 3192 (771) (p < 0.0001)). Subsequently, the titre gradually declined, levelling off after about six months. However, by one year the mean titre (131 (36)) was still higher than the baseline value (p < 0.025).

The pattern of IgG1 results resembled that for IgG. IgG1 titres were detectable in 13 patients (mean 26 (7)). Within 24 hours of treatment with streptokinase the titre decreased to 1 (1.47) (p = 0.003). Subsequently it rose and it was significantly increased by day 4 (mean 79 (27) (p = 0.02)). It reached a peak on day 14 (mean 1751 (589) (p = 0.0004)) and declined to 107 (41) (p < 0.025) by one year. Figure 5 summarises the results.

There was no evidence of IgG2, IgG3, or IgG4 antibodies to streptokinase and only low titres of IgM (<1/30) which did not alter over the period of the study.

There was a large variation in the antibody response. Though the baseline titres were relatively similar for all patients, peak titres for IgG varied from 140 to 10 000, and two patients had peak titres of <200. However, even these patients showed no IgM antibody response to streptokinase even though total IgM and IgG were normal.

The six control patients who did not receive streptokinase had a mean baseline IgG titre of 10 (5) which was similar to that of the patients who received the drug. This titre did not change in the 28 days after the infarct (day 1 = 14 (7); day 4 = 11 (6); day 14 = 19 (5); day 28 = 16 (5)). Nor was there any change in IgG1 antibody titre over the same period.

Total IgG and IgM results were normal for all patients (mean total IgG concentrations = 9355 (953) mg/l; IgG range 1400–16400 mg/l; mean total IgM = 1739 mg/l (120); IgM range 525–2540 mg/l).

Discussion

The purpose of this study was to assess the presence and nature of streptokinase antibodies and their response to an intravenous infusion of streptokinase.

Most of the patients (75%) had detectable IgG and IgG1 antibody titres to streptokinase at presentation. The values were relatively low, but they indicate that such antibodies are widespread in the population, presumably as a result of streptococcal infection (none of our patients had been treated previously with streptokinase).

The antibody titres fell within 24 hours of treatment presumably because of combination between the antibody and antigen, streptokinase. Thereafter, the antibody titres increased gradually; they were significantly raised four days after treatment. The titres reached a peak after 14 days and subsequently declined but they had still not returned to baseline values after one year.

This pattern of immunoglobulin change suggests a secondary immune response. The antibodies found both at presentation and in the subsequent response were IgG and of the IgG1 subclass as predicted for a protein antigen such as streptokinase. This pattern of response and the absence of a rise in IgM titre indicate that this is a secondary rather than a primary immune response. The six control patients showed no significant change in titre, again indicating that the antibody response was specific to streptokinase treatment.

Peak antibody titres to streptokinase varied considerably among patients (from 140–10 000 for IgG) with two patients showing only a slight rise (140 and 175) respectively. We do not know whether this represents an extreme
end of the normal range or whether these two subjects have an isolated immune deficiency against protein antigens. Certainly they had no history of recurrent infections. Further studies of their response to other protein or polysaccharide antigens, however, would be needed to rule out this possibility.

The time course of the secondary immune response seen here resembles that described by Jalihal et al "for streptokinase neutralising capacity", indicating that the neutralisation is probably due to antibody. Jalihal et al suggested that the streptokinase dose should be titrated to overcome this neutralising capacity in patients in whom it is high. Our study suggests that if antibody is responsible for neutralisation, the dose would need to be increased if a patient presented with a second myocardial infarction within one year of the initial treatment. The administration of an increased dose of streptokinase within this period could lead to an immune reaction as well as a failure to achieve an adequate thrombolytic state. However, this possibility remains theoretical at present and further studies will be required to clarify the role and implications of these antibodies. Nevertheless, until their role has been clarified, it would be prudent to avoid repeating the dose between three days and at least one year after the initial therapy. During this period an alternative non-streptokinase thrombolytic agent could be used.